Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

Lenacapavir is a major step forward in HIV prevention. With just two injections a year, it is a simple and highly effective ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming infected with HIV. But big questions remain over the drug’s affordability.

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking studies, Gilead Sciences’ shot, a drug named lenacapavir, nearly eliminated new ...

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much ...